These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 38903939

  • 21. Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004-2021).
    Hu Y, Chen J, Huang L, Liu C, Zhou H, Zhang R.
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36753319
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
    [Abstract] [Full Text] [Related]

  • 28. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
    Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A.
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383659
    [Abstract] [Full Text] [Related]

  • 29. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP.
    Eur J Clin Microbiol Infect Dis; 2024 Sep; 43(9):1787-1794. PubMed ID: 38995343
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D, Stone GG.
    BMC Infect Dis; 2021 Jun 23; 21(1):600. PubMed ID: 34162341
    [Abstract] [Full Text] [Related]

  • 32. Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying blaKPC-2 Reveals a Heterogenous Population and Reversible Genotype.
    Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA, MacVane SH.
    mSphere; 2018 Sep 26; 3(5):. PubMed ID: 30258039
    [Abstract] [Full Text] [Related]

  • 33. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
    Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK.
    Antimicrob Agents Chemother; 2017 Nov 26; 61(11):. PubMed ID: 28827415
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.
    J Antimicrob Chemother; 2018 Oct 01; 73(10):2777-2781. PubMed ID: 30010951
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.
    González-Pinto L, Alonso-García I, Blanco-Martín T, Camacho-Zamora P, Fraile-Ribot PA, Outeda-García M, Lasarte-Monterrubio C, Guijarro-Sánchez P, Maceiras R, Moya B, Juan C, Vázquez-Ucha JC, Beceiro A, Oliver A, Bou G, Arca-Suárez J.
    J Antimicrob Chemother; 2024 Oct 01; 79(10):2591-2597. PubMed ID: 39073766
    [Abstract] [Full Text] [Related]

  • 38. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.
    Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M.
    Microb Drug Resist; 2021 Mar 01; 27(3):342-349. PubMed ID: 32762605
    [Abstract] [Full Text] [Related]

  • 39. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
    Arca-Suárez J, Lasarte-Monterrubio C, Rodiño-Janeiro BK, Cabot G, Vázquez-Ucha JC, Rodríguez-Iglesias M, Galán-Sánchez F, Beceiro A, González-Bello C, Oliver A, Bou G.
    J Antimicrob Chemother; 2021 Jan 01; 76(1):91-100. PubMed ID: 33083833
    [Abstract] [Full Text] [Related]

  • 40. In Vitro Activity of Ceftazidime-Avibactam Alone and in Combination with Amikacin Against Colistin-Resistant Gram-Negative Pathogens.
    Chen T, Xu W, Yu K, Zeng W, Xu C, Cao J, Zhou T.
    Microb Drug Resist; 2021 Mar 01; 27(3):401-409. PubMed ID: 32721272
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.